GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BPH Global Ltd (ASX:BP8) » Definitions » Net-Net Working Capital

BPH Global (ASX:BP8) Net-Net Working Capital : A$0.00 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is BPH Global Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

BPH Global's Net-Net Working Capital for the quarter that ended in Dec. 2023 was A$0.00.

The industry rank for BPH Global's Net-Net Working Capital or its related term are showing as below:

ASX:BP8's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.96
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

BPH Global Net-Net Working Capital Historical Data

The historical data trend for BPH Global's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BPH Global Net-Net Working Capital Chart

BPH Global Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.02 - -

BPH Global Semi-Annual Data
Dec07 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Competitive Comparison of BPH Global's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BPH Global's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BPH Global's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where BPH Global's Price-to-Net-Net-Working-Capital falls into.



BPH Global Net-Net Working Capital Calculation

BPH Global's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2023 is calculated as

Net-Net Working Capital(A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.511+0.75 * 0+0.5 * 0-1.282
-0-0.171)/256.946
=-0.00

BPH Global's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.368+0.75 * 0.254+0.5 * 0.033-1.287
-0-0.032)/367.113
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


BPH Global  (ASX:BP8) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


BPH Global Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of BPH Global's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


BPH Global (ASX:BP8) Business Description

Traded in Other Exchanges
N/A
Address
96 Elizabeth Street, Block Arcade, Office 324, Level 3, Melbourne, VIC, AUS, 3000
BPH Global Ltd, formerly Stemcell United Ltd is a marine and agricultural biotechnology industry. Its only operating segment is sourcing, producing, marketing, and selling traditional medicines. The company's geographical segment includes Australia; Singapore; Malaysia and Greater China. The company's product comprises Cannabis sativa; Dendrobium Officinale and Daemonorops Draco Blume.

BPH Global (ASX:BP8) Headlines

No Headlines